Kohei Tsuji
Overview
Explore the profile of Kohei Tsuji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kobayakawa T, Yokoyama M, Tsuji K, Boku S, Kurakami M, Fujino M, et al.
Chem Pharm Bull (Tokyo)
. 2024 Jan;
72(1):41-47.
PMID: 38171903
The capsid of human immunodeficiency virus type 1 (HIV-1) forms a conical structure by assembling oligomers of capsid (CA) proteins and is a virion shell that encapsulates viral RNA. The...
12.
Tsuji K, Kobayakawa T, Ishii T, Higashi-Kuwata N, Azuma C, Shinohara K, et al.
Chem Pharm Bull (Tokyo)
. 2023 Dec;
71(12):879-886.
PMID: 38044140
In the development of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drugs, its main protease (M), which is an essential enzyme for viral replication, is a promising target. To date,...
13.
Kobayakawa T, Amano M, Nakayama M, Tsuji K, Ishii T, Miura Y, et al.
RSC Med Chem
. 2023 Oct;
14(10):1973-1980.
PMID: 37859721
Hepatitis B is a viral hepatitis, which is caused by infection of hepatitis B virus (HBV). This disease progresses to chronic hepatitis, cirrhosis and liver cancer. To treat hepatitis B,...
14.
Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Shinohara K, Azuma C, et al.
J Med Chem
. 2023 Sep;
66(19):13516-13529.
PMID: 37756225
The main protease (M) of SARS-CoV-2 is an attractive target for the development of drugs to treat COVID-19. Here, we report the design, synthesis, and structure-activity relationship (SAR) studies of...
15.
Ishii T, Kobayakawa T, Matsuda K, Tsuji K, Ohashi N, Nakahata S, et al.
Eur J Med Chem
. 2023 May;
256:115449.
PMID: 37224601
Cells latently infected with human immunodeficiency virus type 1 (HIV-1) prevent people living with HIV-1 from obtaining a cure to the infectious disease. Latency reversing agents (LRAs) such as protein...
16.
Tsuji K, Baffour-Awuah Owusu K, Miura Y, Ishii T, Shinohara K, Kobayakawa T, et al.
RSC Adv
. 2023 Mar;
13(13):8779-8793.
PMID: 36950081
Membrane fusion is a critical and indispensable step in the replication cycles of viruses such as SARS-CoV-2 and human immunodeficiency virus type-1 (HIV-1). In this step, a trimer of the...
17.
Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, et al.
Nat Commun
. 2023 Feb;
14(1):1076.
PMID: 36841831
COVID-19 caused by SARS-CoV-2 has continually been serious threat to public health worldwide. While a few anti-SARS-CoV-2 therapeutics are currently available, their antiviral potency is not sufficient. Here, we identify...
18.
Kobayakawa T, Yokoyama M, Tsuji K, Fujino M, Kurakami M, Onishi T, et al.
RSC Adv
. 2023 Jan;
13(3):2156-2167.
PMID: 36712613
The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among...
19.
Matsuura K, Yamaura M, Sakawaki H, Himeno A, Pisil Y, Kobayakawa T, et al.
Virology
. 2022 Dec;
578:171-179.
PMID: 36580864
By acclimatizing CCR5-tropic tier 1B SHIV-MK1 to rhesus monkeys, a tier 2 SHIV-MK38 strain with neutralization resistance and high replication ability was generated. In this study, we generated SHIV-MK38C, a...
20.
Matsumoto K, Kuwata T, Tolbert W, Richard J, Ding S, Prevost J, et al.
J Virol
. 2022 Dec;
97(1):e0163822.
PMID: 36511698
Small CD4-mimetic compound (CD4mc), which inhibits the interaction between gp120 with CD4, acts as an entry inhibitor and induces structural changes in the HIV-1 envelope glycoprotein trimer (Env) through its...